Free Trial

Invesco Ltd. Reduces Stock Position in AMERISAFE, Inc. (NASDAQ:AMSF)

AMERISAFE logo with Finance background

Invesco Ltd. reduced its stake in shares of AMERISAFE, Inc. (NASDAQ:AMSF - Free Report) by 6.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 158,469 shares of the insurance provider's stock after selling 10,409 shares during the period. Invesco Ltd. owned 0.83% of AMERISAFE worth $8,167,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC raised its position in shares of AMERISAFE by 63.4% during the 4th quarter. GAMMA Investing LLC now owns 1,343 shares of the insurance provider's stock worth $69,000 after purchasing an additional 521 shares during the last quarter. R Squared Ltd purchased a new position in AMERISAFE during the fourth quarter worth about $99,000. KLP Kapitalforvaltning AS purchased a new position in AMERISAFE during the fourth quarter worth about $180,000. Virtu Financial LLC purchased a new position in shares of AMERISAFE in the 3rd quarter worth about $200,000. Finally, Versor Investments LP purchased a new position in shares of AMERISAFE in the 4th quarter worth about $205,000. 97.41% of the stock is currently owned by institutional investors and hedge funds.

AMERISAFE Trading Down 0.8 %

Shares of AMERISAFE stock traded down $0.41 during trading hours on Tuesday, reaching $48.61. The stock had a trading volume of 10,481 shares, compared to its average volume of 109,607. The firm has a 50 day simple moving average of $50.47 and a two-hundred day simple moving average of $52.24. The firm has a market capitalization of $925.98 million, a price-to-earnings ratio of 15.23 and a beta of 0.34. AMERISAFE, Inc. has a 1 year low of $41.97 and a 1 year high of $60.24.

AMERISAFE (NASDAQ:AMSF - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The insurance provider reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.07. The company had revenue of $73.51 million for the quarter, compared to the consensus estimate of $77.37 million. AMERISAFE had a return on equity of 16.50% and a net margin of 19.49%. Sell-side analysts forecast that AMERISAFE, Inc. will post 2.45 EPS for the current year.

AMERISAFE Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 21st. Investors of record on Friday, March 7th were issued a dividend of $0.39 per share. The ex-dividend date of this dividend was Friday, March 7th. This represents a $1.56 annualized dividend and a dividend yield of 3.21%. AMERISAFE's payout ratio is currently 53.98%.

About AMERISAFE

(Free Report)

AMERISAFE, Inc, an insurance holding company, underwrites workers' compensation insurance in the United States. The company provides benefits to injured employees for temporary or permanent disability, death, and medical and hospital expenses. It sells its products through retail and wholesale brokers and agents; and small and mid-sized employers engaged in hazardous industries, including construction, trucking, logging and lumber, agriculture, manufacturing, telecommunications, and maritime.

Read More

Institutional Ownership by Quarter for AMERISAFE (NASDAQ:AMSF)

Should You Invest $1,000 in AMERISAFE Right Now?

Before you consider AMERISAFE, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AMERISAFE wasn't on the list.

While AMERISAFE currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Blowout Earnings Winners That Could Soar Even Higher
5 Stocks You’ve Never Heard Of That I’m Buying Nonstop in 2025
3 Sectors With Massive Momentum You Can’t Afford to Miss

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines